15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Sarepta Therapeutics Inc, 7 rate it Buy or better, 8 sit at Hold, and 5 rate it Sell or worse, a hold consensus. The target range is very wide, $5.00 to $50.00 (about 10.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $22.59 sits 46% above the current $15.45. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.48 next quarter toward $2.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Hold
Strong Buy00%
Buy735%
Hold840%
Sell525%
Strong Sell00%
Based on 20 analysts giving stock ratings to Sarepta Therapeutics Inc.
As of Jul, 7 of 17 firms rate SRPT a Buy (5 Hold, 5 Sell), the standing distribution of every covering firm's most recent active call.
SRPT EPS & revenue forecast
EPS · NEXT QUARTER
$0.48
Range $0.16 – $0.64 · 9 analysts · -473% YoY
Next period, 9 analysts expect Sarepta Therapeutics Inc to earn $0.48 a share (range $0.16 – $0.64), versus $-0.13 a year earlier. Full-year consensus is $4.79, growing to $2.45 the year after.
REVENUE · NEXT QUARTER
$370.9M
Range $317.9M – $452.0M · 9 analysts · -7% YoY
Revenue is expected to reach $370.9M (range $317.9M – $452.0M), -7.1% year-over-year. Full-year consensus is $1.8B, rising to $1.4B next year.
Top analysts covering Sarepta Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SRPT.
#1
Anupam Rama
JP Morgan · Rank #62
Hold
$19.00+23.0% to target
Overall win rate
46%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #131
Sell
$13.00-15.9% to target
Overall win rate
43%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #162
Hold
$21.00+35.9% to target
Overall win rate
38%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Sell
$5.00-67.6% to target
Overall win rate
34%
+ Follow
#5
TA
Tazeen Ahmad
B of A Securities · Rank #275
Sell
$19.00+23.0% to target
Overall win rate
41%
+ Follow
SRPT stock forecast FAQ
What is SRPT's average 12-month price target?+
The 17 analysts with a live target average $22.59 for Sarepta Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $5.00 low.
Is SRPT stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 20 analyst ratings, 7 are Buy or Strong Buy, 8 are Hold, and 5 are Sell or Strong Sell.
What are the highest and lowest price targets for SRPT?+
The Street-high target is $50.00 (BMO Capital), and the Street-low is $5.00 (HC Wainwright & Co.). The average of all 17 active targets is $22.59.
How many Wall Street analysts cover SRPT?+
20 analysts have an active rating on Sarepta Therapeutics Inc, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering SRPT?+
Among analysts who currently cover SRPT, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Hold with a $19.00 target.
What is Sarepta Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.48 per share (range $0.16 – $0.64) across 9 analysts. Full-year EPS is projected at $4.79, rising to $2.45 the following year.
How much revenue is Sarepta Therapeutics Inc expected to report next quarter?+
Consensus revenue is $370.9M (range $317.9M – $452.0M). Full-year revenue is projected at $1.8B, growing to $1.4B next year.
Have analysts been upgrading or downgrading SRPT lately?+
As of Jul, 7 of 17 firms rate SRPT a Buy (5 Hold, 5 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SRPT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
